RxDoctor Payments Data

Grace Lessing, MD

Ophthalmology · East Patchogue, NYNPI 1588733141

Payments from drug & device makers

$1,932in general payments, 2019–2025

Across 67 payments — averaging $28.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$842
  • Alcon$332
  • Oyster Point Pharma, Inc.$190
  • NEW World Medical,inc.$118
  • Amgen$115
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$61
  • plus $274 from 10 others

What the payments were for

  • Food & beverage$1,91499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,932 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$357,890
Medicare patients
759
Services billed
3,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine142$185,584
XiidraLifitegrast60$43,815
LumiganBimatoprost63$37,591
RhopressaNetarsudil Mesylate65$28,238
CombiganBrimonidine Tartrate/Timolol37$24,212
Restasis MultidoseCyclosporine25$17,895
Alphagan PBrimonidine Tartrate42$16,187
Cyclosporine34$15,236
Bromfenac Sodium77$10,753
Prednisolone Acetate226$10,239
VyzultaLatanoprostene Bunod13$9,960
RocklatanNetarsudil Mesylat/Latanoprost24$9,531
SimbrinzaBrinzolamide/Brimonidine Tart39$9,502
IlevroNepafenac19$6,979
Timolol Maleate107$6,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Alphagan P$842$281,469309 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$52$53,77573 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Zylet, Loteprednol Etabonate$61$11,75745 claims
AlconSimbrinza$332$9,50239 claims
NovartisIlevro$24$6,97919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in East Patchogue

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →